Pharmala Biotech (MDMA) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
29 Dec, 2025Executive summary
Major steps taken in late 2025 and Q1 2026 to advance novel molecule development, aiming to start Phase 2a/b clinical trials in Australia.
Demand for LaNeo MDMA continues to grow, supported by reimbursement approvals in Australia.
Financial highlights
Customer deposits increased by $150k in year-end 2025, offset by $83k recognized revenue, totaling $276k compared to $209k a year earlier.
Q1 2026 saw a $225k increase in deposits, offset by $68k recognized revenue, totaling $433k compared to $276k at the end of 2025.
Deposits typically represent 50% of contract value, with revenue recognized upon product shipment and regulatory approval.
Outlook and guidance
Anticipates continued momentum in development and clinical trial pipeline growth throughout fiscal 2026.
Expects further growth in clinical trial sales due to expanded reimbursement in Australia.
Latest events from Pharmala Biotech
- Revenue surged 95% with improved EBITDA and a $1.56M private placement completed.MDMA
Q4 202429 Dec 2025 - Revenue surged 95% year-over-year, with operational gains and expanded distribution.MDMAQ2 202529 Dec 2025
- Revenue up 95% year-over-year but quarterly sales fell; new funding supports future growth.MDMAQ1 202524 Dec 2025
- MDMA therapy delivers rapid PTSD remission and global expansion, backed by innovation and strong IP.MDMASmall Cap Growth Virtual Investor Conference 202520 Oct 2025
- Net loss widened on lower revenue and higher expenses, despite strengthened liquidity from new financing.MDMAQ3 202518 Aug 2025
- Revenue up, net loss down, and key IP and joint venture milestones achieved.MDMAQ3 202413 Jun 2025